Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*15:01&MBP (ENPVVHFFKNIVTPR) Complex Protein (Monomer, MALS verified)

Artikelnummer: ABS-HLM-H82EA-25UG
Artikelname: Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*15:01&MBP (ENPVVHFFKNIVTPR) Complex Protein (Monomer, MALS verified)
Artikelnummer: ABS-HLM-H82EA-25UG
Hersteller Artikelnummer: HLM-H82Ea-25ug
Alternativnummer: ABS-HLM-H82EA-25UG
Hersteller: AcroBiosystems
Wirt: Human
Kategorie: Proteine/Peptide
Spezies Reaktivität: Human
Konjugation: Biotin
The peptide ENPVVHFFKNIVTPR, derived from myelin basic protein (MBP), is presented by the MHC class II heterodimer HLADRA1*01:01/HLADRB1*15:01. This specific peptideMHC II complex is a predominant autoantigen target in multiple sclerosis (MS) and is strongly associated with the HLADRB1*15:01 genetic risk allele. Its recognition by autoreactive CD4 T helper cells initiates and drives the inflammatory immune response against the myelin sheath in the central nervous system, making it a prototypical complex for studying autoimmune demyelination and MS pathogenesis. - Proteine/Peptide
Molekulargewicht: 29.8 kDa and 29.2 kDa
Tag: C-10*His & C-Avi
NCBI: 2388006
Puffer: PBS, pH7.4
Reinheit: 90%
Formulierung: Powder
Target-Kategorie: HLA-DRA1*0101 & HLA-DRB1*1501 & MBP(ENPVVHFFKNIVTPR)
Immobilized Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*15:01&MBP (ENPVVHFFKNIVTPR) Complex Protein (Cat. No. HLM-H82Ea) at 1 µg/mL (100 µL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 µg/well) plate can bind Anti-HLA-DR Antibody, Human IgG1 with a linear range of 0.06-2 ng/mL (QC tested).
Immobilized Anti-HLA-DR Antibody, Human IgG1 at 1 µg/mL (100 µL/well) can bind Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*15:01&MBP (ENPVVHFFKNIVTPR) Complex Protein (Cat. No. HLM-H82Ea) with a linear range of 0.5-16 ng/mL (Routinely tested).
Biotinylated Human HLA-DRA1*01:01&HLA-DRB1*15:01&MBP (ENPVVHFFKNIVTPR) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.